全文获取类型
收费全文 | 412篇 |
免费 | 12篇 |
专业分类
儿科学 | 12篇 |
妇产科学 | 20篇 |
基础医学 | 35篇 |
临床医学 | 22篇 |
内科学 | 39篇 |
神经病学 | 3篇 |
特种医学 | 2篇 |
外科学 | 45篇 |
综合类 | 1篇 |
预防医学 | 32篇 |
药学 | 56篇 |
肿瘤学 | 157篇 |
出版年
2022年 | 1篇 |
2021年 | 10篇 |
2019年 | 4篇 |
2018年 | 2篇 |
2017年 | 2篇 |
2015年 | 2篇 |
2014年 | 6篇 |
2013年 | 5篇 |
2012年 | 7篇 |
2011年 | 9篇 |
2010年 | 11篇 |
2009年 | 12篇 |
2008年 | 31篇 |
2007年 | 31篇 |
2006年 | 24篇 |
2005年 | 15篇 |
2004年 | 19篇 |
2003年 | 22篇 |
2002年 | 12篇 |
2001年 | 25篇 |
2000年 | 15篇 |
1999年 | 21篇 |
1998年 | 8篇 |
1997年 | 2篇 |
1996年 | 4篇 |
1995年 | 5篇 |
1994年 | 8篇 |
1993年 | 3篇 |
1992年 | 8篇 |
1991年 | 11篇 |
1990年 | 13篇 |
1989年 | 4篇 |
1988年 | 6篇 |
1987年 | 6篇 |
1986年 | 7篇 |
1985年 | 9篇 |
1984年 | 8篇 |
1983年 | 5篇 |
1982年 | 6篇 |
1981年 | 1篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1977年 | 5篇 |
1976年 | 3篇 |
1975年 | 1篇 |
1974年 | 3篇 |
1966年 | 1篇 |
1939年 | 1篇 |
排序方式: 共有424条查询结果,搜索用时 8 毫秒
1.
The reactions of corresponding 2,3-diamino-pyridines with succinic anhydride were carried out. 3-(2-Imidazo[4,5-b]pyridine)propionic acid and its N-1 and N-3 methyl derivatives were isolated. The acids obtained were converted into the esters, amides, nitriles, thioamides, amidoximes and hydrazides. Some of the synthesized compounds were tested for tuberculostatic activity. 相似文献
2.
Summary Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer. The dose of dipyridamole was fixed at 175 mg/m2 by mouth every 6 h (700 mg/m2/day), based upon a previous phase I trial of oral dipyridamole with 5-FU and leukovorin. Dipyridamole therapy began 24 h prior to the first dose of chemotherapy and continued until 24 h after the last dose of chemotherapy for each course of treatment. At the initial dose level, leukovorin 200 mg/m2 was given intravenously immediately prior to 5-FU 375 mg/ m2 intravenously on days 1–5. Mitoxantrone 6 mg/m2 was given as a single dose on day 3. Unacceptable toxicity was observed at this dose level, leading to successive dose decrements rather than dose increments. The maximum tolerated dose was leukovorin 200 mg/m2 days 1–2, 5-FU 375 mg/m2 days 1–2, mitoxantrone 6 mg/m2 on day 2, and dipyridamole 175 mg/m2 every 6 h on days 0–3. Two responses were produced in 15 patients. This regimen is not recommended for further investigation in the treatment of breast cancer. 相似文献
3.
4.
Peer relationships and adjustment in children with cancer 总被引:4,自引:4,他引:0
R B Noll S LeRoy W M Bukowski F A Rogosch R Kulkarni 《Journal of pediatric psychology》1991,16(3):307-326
Evaluated the psychosocial adaptations of children with cancer (n = 24, ages 8-18) as compared with same classroom controls on indices of (a) peer- and self-perceptions of sociability, aggression, and social isolation; (b) overall popularity; (c) mutual friendships; (d) feelings of loneliness; and (e) self-concept in multiple domains. Although the peer report data showed that children with cancer had a social reputation as significantly more socially isolated, no significant differences were found for their popularity, number of mutual friends, loneliness, or self-worth. Findings suggest that children with cancer have a reputation as more socially isolated, but differences were not found on measures of acceptance by peers, self-concept, or loneliness. 相似文献
5.
6.
Malone FD Canick JA Ball RH Nyberg DA Comstock CH Bukowski R Berkowitz RL Gross SJ Dugoff L Craigo SD Timor-Tritsch IE Carr SR Wolfe HM Dukes K Bianchi DW Rudnicka AR Hackshaw AK Lambert-Messerlian G Wald NJ D'Alton ME;First- Second-Trimester Evaluation of Risk 《The New England journal of medicine》2005,353(19):2001-2011
7.
8.
Kumar Rajagopalan David Peereboom G. Thomas Budd Thomas Olencki Siva Murthy Paul Elson Denise McLain Ronald Bukowski 《Investigational new drugs》1999,16(3):255-258
Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered.Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer. 相似文献
9.
Cancer and noncancer health effects have traditionally been handled differently in quantitative risk assessment. A threshold (i.e., safe exposure) has been assumed for noncancer health effects, and low-dose linearity without a threshold has been assumed for cancer. “Harmonization” attempts to reconcile these contrasting assumptions under one paradigm. Recent regulatory initiatives suggest that the U.S. Environmental Protection Agency may be leaning toward a harmonized, probabilistic/linear approach for noncancer health effects. Proponents of this approach cite variability in human susceptibility as an argument against thresholds (i.e., some individuals may be exquisitely sensitive at exposures well below threshold levels). They also cite the results of epidemiological models that suggest low-dose linearity for noncancer health effects. We will discuss the implications of these arguments and compare them to what is known about human biological variability in general. We will also touch on the regulatory implications of hormesis within this framework. 相似文献
10.